Clinical Trials Logo

Hepatic Cell Carcinoma clinical trials

View clinical trials related to Hepatic Cell Carcinoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT06265272 Recruiting - Liver Cirrhosis Clinical Trials

Value of [68Ga]Ga-PSMA-11 PET/MRI in the Assessment of Liver Cirrhosis

Start date: December 10, 2023
Phase:
Study type: Observational

A total of fifty-five (55) patients with liver cirrhosis will be enrolled in this study to produce and validate dedicated Ga-PSMA-PET/MRI acquisition protocols. The specific hypotheses include: - Ga-PSMA PET/MRI may allow robust and reproducible noninvasive in vivo quantitation of hepatic macro and microhemodynamics in cirrhotic patients - Dedicated simultaneously acquired DWI sequences might quantitate liver fibrosis and improve hemodynamic quantitation. - Ga-PSMA PET/MRI may allow noninvasive and reproducible quantitation of portal venous hypertension and predict its evolution, as well as response to treatments - Ga-PSMA PET/MRI may improve noninvasive and reproducible qualitative and quantitative assessment of liver function, structure, nodules and predict evolution of cirrhosis

NCT ID: NCT06144385 Recruiting - Liver Carcinoma Clinical Trials

A Phase 1, Single-arm, Open-label, Dose-escalation Study of JWATM204 as T Cell-targeted Immunotherapy in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma

Start date: March 24, 2022
Phase: Phase 1
Study type: Interventional

This is a single arm, open-label, dose escalation clinical study to evaluate the safety and efficacy of infused autologous GPC3-directed CAR-T in patients with advanced hepatocellular carcinoma refractory to prior systematic treatments.

NCT ID: NCT06042842 Not yet recruiting - Clinical trials for Hepatic Cell Carcinoma

The Value of circRNAs (hsa_circ_0004001) in Early Diagnosis of HCC

Start date: November 2023
Phase:
Study type: Observational

1. To evaluate the clinical utility of plasma circRNAs (hsa_circ_0004001) as a non invasive diagnostic biomarker for HCC patients and to differentiate between malignant and nonmalignant hepatic disorders. 2. To study the relation of circRNAs (hsa_circ_0004001) to HCC staging. 3. To compare between circRNAs (hsa_circ_0004001) and the routine marker (AFP) as biomarkers for HCC diagnosis.

NCT ID: NCT04048317 Not yet recruiting - Clinical trials for Hepatic Cell Carcinoma

Effectiveness of Drug Eluting TACE in Primary HCC

Start date: September 1, 2019
Phase: Early Phase 1
Study type: Interventional

the aim of this work to compare effectiveness of drug-eluting bead trans-arterial chemo-embolization and conventional trans-arterial chemo-embolization of hepatic cell carcinoma in the aspect of (Tumor response via m-RECIST criteria), (liver injury via Liver function tests and tumor markers) and (survival outcome) of patients treated in Assiut university .